Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal study

非典型阿尔茨海默病的分子和结构成像：一项纵向研究

• 批准号: 9889014
• 负责人: Jennifer Louise Whitwell
• 金额: $ 39.08万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-04-01 至 2021-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9889014
• 关键词: Affect; Alzheimer' s Disease; American; Amyloid beta-Protein; Anomia; Aphasia; Atrophic; Autopsy; Binding; Biological; Biological Markers; Biology; Brain; Brain Injuries; Cause of Death; Clinic; Clinical; Clinical Trials; Cognitive; Deposition; Development; Diffusion Magnetic Resonance Imaging; Disease; Disease Progression; Future; Goals; Grant; Human; Image; Imaging Techniques; Impaired cognition; Knowledge; Language; Life; Ligands; Longitudinal Studies; Magnetic Resonance Imaging; Measures; Memory Loss; Molecular; Molecular Structure; Neurologic; Neuropsychological Tests; Pathologic; Pathology; Patients; Pattern; Pittsburgh Compound-B; Positron-Emission Tomography; Proteins; Public Health; Research; Retrieval; Sample Size; Statistical Models; Structure; Syndrome; Time; Variant; Visuospatial; abeta deposition; cerebral atrophy; cohort; gray matter; hyperphosphorylated tau; imaging biomarker; imaging modality; longitudinal positron emission tomography; neuroimaging; neuroimaging marker; protein distribution; public health relevance; recruit; tau Proteins; treatment effect; white matter

 DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a major public health problem affecting over 5 million people in the US. Patients with AD have beta-amyloid (Aβ) and tau pathology and typically present with memory loss. However, approximately 25% of AD subjects do not present with early memory loss and instead present with other cognitive complaints, and are referred to as atypical AD. The most common atypical AD syndromes include logopenic aphasia (LPA), a language syndrome, and posterior cortical atrophy (PCA), a visuospatial/perceptual syndrome. The biological underpinnings of these atypical AD syndromes are unclear. The goal of this R01 is to use longitudinal molecular PET (Aβ and tau-PET imaging) and structural MRI to assess the relationship between Aβ and tau deposition and structural brain damage in LPA, PCA and typical AD, with the ultimate goal of increasing our understanding of disease biology in these syndromic variants of AD. These analyses will also allow the assessment of neuroimaging biomarkers of disease progression that could be useful in future clinical trials. To accomplish our aims we will recruit 60 subjects that fulfill clinical criteria for LPA (n=30) or PCA (n=30) and show Aβ deposition on PET imaging. Each subject will undergo two serial assessments 24 months apart that will include neurological and neuropsychological testing, 3T structural MRI and diffusion tensor imaging, Pittsburgh Compound B PET and tau-PET performed with the AV-1451 ligand. These subjects will be compared to typical AD and cognitively normal cohorts already followed at Mayo Clinic. The regional distribution of Aβ and tau deposition, and change in protein deposition over time, will b assessed for LPA, PCA and typical AD. The relationship between protein deposition and grey matter atrophy and white matter tract degeneration will also be assessed. Region-level measures will then be generated from each imaging modality and statistical modelling will be used to determine what regions, or combinations of regions, provides the optimum biomarkers of disease progression. Biomarkers will be validated by generating sample size estimates for clinical trials and assessing the relationship with cognitive decline. Our R01 will have a major impact on public health since atypical AD effects ~1,000,000 Americans. Our research will increase understanding of disease biology and progression in LPA and PCA and provide biomarkers which will allow the inclusion of these subjects in future trials.

 描述（由适用提供）：阿尔茨海默氏病（AD）是影响美国超过500万人的主要公共卫生问题。 AD患者患有β-淀粉样蛋白（Aβ）和TAU病理学，通常伴有记忆丧失。但是，大约25％的AD受试者没有早期记忆力丧失，而是出现其他认知投诉，被称为非典型AD。最常见的非典型AD综合症包括徽标失语症（LPA），语言综合征和后皮质萎缩（PCA），一种视觉/感知综合征。这些非典型AD综合征的生物基础尚不清楚。该R01的目的是使用纵向分子PET（Aβ和TAU-PET成像）和结构MRI来评估LPA，PCA和典型AD中Aβ和TAU沉积与结构性脑损伤之间的关系，其最终目的是增加我们对这些AD综合症疾病生物学的理解。这些分析还将允许评估疾病进展的神经影像标志物，这在将来的临床试验中可能很有用。为了实现我们的目标，我们将招募60个实现临床的主题 LPA（n = 30）或PCA（n = 30）的标准，并在PET成像上显示Aβ。每个受试者将进行两次连续评估24个月，包括神经系统和神经心理学测试，3T结构MRI和扩散张量成像，匹兹堡化合物B PET和使用AV-1451配体进行的TAU-PET。这些受试者将与梅奥诊所已经遵循的典型AD和典型的正常人群进行比较。 Aβ和TAU沉积的区域分布以及蛋白质沉积随时间的变化，将评估LPA，PCA和典型AD的b。还将评估蛋白质沉积与灰质萎缩与白质变性之间的关系。然后，将从每种成像方式中产生区域级别的措施，并将使用统计建模来确定哪些区域或区域组合提供了疾病进展的最佳生物标志物。生物标志物将通过生成临床试验的样本量估计值并评估与认知能力下降的关系来验证。自非典型广告效果以来，我们的R01将对公共卫生产生重大影响。我们的研究将增加对LPA和PCA疾病生物学和进展的理解，并提供生物标志物，从而使这些受试者将这些受试者纳入以后的试验。